USNA Stock Forecast 2025-2026
Distance to USNA Price Targets
USNA Price Momentum
10 Quality Stocks Worth Considering Now
Researching USANA (USNA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on USNA and similar high-potential opportunities.
Latest USNA Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, USNA has a neutral consensus with a median price target of $50.50 (ranging from $36.00 to $65.00). Currently trading at $29.14, the median forecast implies a 73.3% upside. This outlook is supported by 0 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Linda Bolton Weiser at DA Davidson, suggesting a 23.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
USNA Analyst Ratings
USNA Price Target Range
Latest USNA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for USNA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 27, 2025 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $36.00 |
| Jan 2, 2025 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $38.00 |
| Oct 23, 2024 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $35.00 |
| Jul 25, 2024 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $38.00 |
| May 7, 2024 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $46.00 |
| Feb 22, 2024 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $48.00 |
| Oct 25, 2023 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $53.00 |
| Apr 26, 2023 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $56.00 |
| Feb 13, 2023 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $52.50 |
| Oct 27, 2022 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $49.00 |
| Jul 28, 2022 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $57.00 |
| Jul 12, 2022 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $58.00 |
| Jul 7, 2022 | Jefferies | Stephanie Wissink | Underperform | Downgrade | $53.00 |
| Apr 27, 2022 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $76.00 |
| Apr 14, 2022 | DA Davidson | Neutral | Initiates | $0.00 | |
| Feb 10, 2021 | Roth Capital | David Bain | Buy | Maintains | $126.00 |
| Dec 17, 2020 | Roth Capital | Buy | Initiates | $0.00 | |
| Aug 22, 2019 | Jefferies | Hold | Initiates | $0.00 | |
| Jul 3, 2019 | Sidoti & Co. | Neutral | Downgrade | $70.00 | |
| Apr 16, 2019 | Tigress Financial | Buy | Initiates | $0.00 |
Usana Health Sciences, Inc. (USNA) Competitors
The following stocks are similar to USANA based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Usana Health Sciences, Inc. (USNA) Financial Data
Usana Health Sciences, Inc. has a market capitalization of $550.88M with a P/E ratio of 13.3x. The company generates $854.50M in trailing twelve-month revenue with a 4.9% profit margin.
Revenue growth is -3.4% quarter-over-quarter, while maintaining an operating margin of +3.8% and return on equity of +7.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Usana Health Sciences, Inc. (USNA) Business Model
About Usana Health Sciences, Inc.
Develops and distributes nutritional supplements.
Usana operates on a direct selling model, which allows it to market its nutritional supplements and personal care products while empowering entrepreneurs globally. The company generates revenue through the sale of its high-quality vitamins, dietary supplements, and skin care items directly to consumers.
Founded in 1992, Usana prioritizes scientific research and product efficacy, establishing itself as a trusted brand among health-conscious consumers and professionals. The company is well-positioned in the growing health and wellness market, aligning with global trends towards preventive health and personalized solutions.
Company Information
Sector
Consumer Defensive
Industry
Packaged Foods
Employees
1,700
CEO
Mr. Jim Brown
Country
United States
IPO Year
1995
Website
www.usana.comUsana Health Sciences, Inc. (USNA) Latest News & Analysis
USANA Exec. Chairman Kevin Guest Invites All to Celebrate March's Listening Awareness Month
13 days agoUSANA's Executive Chairman Kevin Guest promotes March's Listening Awareness Month, highlighting the value of active listening in enhancing relationships and understanding.
USANA's support for Listening Awareness Month highlights its focus on culture and employee engagement, which can enhance productivity and improve brand reputation, potentially impacting its stock performance.
USANA Health Sciences, Inc. will hold its Q4 2024 Earnings Conference Call on February 26, 2025, at 11:00 AM ET, featuring key company executives and analysts.
The upcoming earnings call for USANA Health Sciences may reveal key financial performance insights, impacting stock valuation and investor sentiment.
USANA Health Sciences reported its fiscal Q4 and year-end results for 2024, including the acquisition of a 78.8% stake in Hiya Health Products on December 23, 2024, contributing minimal impact to results.
USANA's acquisition of Hiya Health could enhance growth potential and market position, influencing future earnings and overall investment value. Short-term results may not reflect long-term benefits.
USANA Health Sciences (USNA) reported Q3 earnings of $0.64 per share, surpassing the Zacks estimate of $0.49, though down from $0.87 per share in the same quarter last year.
USANA's earnings beat expectations, indicating stronger performance than anticipated, but a decline from last year's earnings may raise concerns about growth sustainability.
Zacks emphasizes its Rank system based on earnings estimates to identify strong stocks, while also monitoring value, growth, and momentum trends.
The emphasis on earnings estimates and revisions highlights potential stock performance, guiding investors toward high-potential stocks amidst shifting market trends.
The P/B ratio is a tool for finding undervalued stocks with growth potential. Notable stocks include GM, KT, GBX, USNA, and ENS.
The mention of low P/B ratio stocks like GM, KT, GBX, USNA, and ENS signals potential investment opportunities with undervalued growth prospects, attracting investor interest.
Frequently Asked Questions About USNA Stock
What is Usana Health Sciences, Inc.'s (USNA) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Usana Health Sciences, Inc. (USNA) has a median price target of $50.50. The highest price target is $65.00 and the lowest is $36.00.
Is USNA stock a good investment in 2025?
According to current analyst ratings, USNA has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $29.14. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for USNA stock?
Wall Street analysts predict USNA stock could reach $50.50 in the next 12 months. This represents a 73.3% increase from the current price of $29.14. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Usana Health Sciences, Inc.'s business model?
Usana operates on a direct selling model, which allows it to market its nutritional supplements and personal care products while empowering entrepreneurs globally. The company generates revenue through the sale of its high-quality vitamins, dietary supplements, and skin care items directly to consumers.
What is the highest forecasted price for USNA Usana Health Sciences, Inc.?
The highest price target for USNA is $65.00 from at , which represents a 123.1% increase from the current price of $29.14.
What is the lowest forecasted price for USNA Usana Health Sciences, Inc.?
The lowest price target for USNA is $36.00 from Linda Bolton Weiser at DA Davidson, which represents a 23.5% increase from the current price of $29.14.
What is the overall USNA consensus from analysts for Usana Health Sciences, Inc.?
The overall analyst consensus for USNA is neutral. Out of 4 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $50.50.
How accurate are USNA stock price projections?
Stock price projections, including those for Usana Health Sciences, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
